CompletedPhase 1NCT04640480
Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors
Studying Small cell carcinoma of the ovary
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- SN BioScience
- Principal Investigator
- Joohang Kim, DrCHA Medical Center at Bundang
- Intervention
- SNB-101(drug)
- Enrollment
- 21 target
- Eligibility
- 19 years · All sexes
- Timeline
- 2020 – 2026
Study locations (3)
- CHA Medical Center, Seongnam-si, Gyeonggi-do, South Korea
- The Severance Hospital of the Yonsei University, Seoul, Seoul, South Korea
- The Catholic University of Korea Seoul ST. Mary's Hospital, Seoul, Seoul, South Korea
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04640480 on ClinicalTrials.govOther trials for Small cell carcinoma of the ovary
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07424547Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid TumorsConjupro Biotherapeutics, Inc.
- RECRUITINGPHASE1NCT07444814Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid TumorsWhitehawk Therapeutics, Inc.
- RECRUITINGPHASE1NCT06774963A Phase 1 Study of LNCB74 in Advanced Solid TumorsNextCure, Inc.
- RECRUITINGPHASE1, PHASE2NCT06873555A Study of DC05F01 in Chinese Patients with Recurrent/Refractory Ovarian Cancer and Other Advanced Solid TumorsHeronova Pharmaceuticals
- ACTIVE NOT RECRUITINGPHASE1NCT06253520Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic CancerNational Cancer Institute (NCI)
- RECRUITINGPHASE1NCT05104515First-in-human Study of OVM-200 as a Therapeutic Cancer VaccineOxford Vacmedix UK Ltd.
- RECRUITINGPHASE2NCT04602377Addition of Pembrolizumab to the Standard of Care Chemotherapy in Patient With SCCOHTARCAGY/ GINECO GROUP
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT02734004A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.AstraZeneca